SEC Form 4 · accession 0000899243-18-006041
T2 Biosystems, Inc. · TTOO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John M Sprague
Officer — Chief Financial Officer
Period of report
Mar 1, 2018
Accepted (ET)
Mar 2, 2018 · 2:14 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001492674
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $5.08 | Mar 1, 2018 | A | 225,000 | A | — | Mar 1, 2028 | Common Stock | 225,000 | 225,000 | D |
Explanation of responses
- F125% of the total shares vest on 01/30/2019, and the remaining shares vest in substantially equal monthly installments over the following 36 months, to be fully vested on 01/30/2022.